These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 15921958

  • 1. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
    Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, Kallikazaros I.
    Eur J Heart Fail; 2005 Aug; 7(5):882-7. PubMed ID: 15921958
    [Abstract] [Full Text] [Related]

  • 2. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO.
    Heart Lung Circ; 2008 Jun 01; 17(3):206-10. PubMed ID: 18242130
    [Abstract] [Full Text] [Related]

  • 6. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A.
    J Am Coll Cardiol; 2009 Jun 23; 53(25):2343-8. PubMed ID: 19539144
    [Abstract] [Full Text] [Related]

  • 7. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Põder P, Sarapohja T.
    Eur J Heart Fail; 2008 Dec 23; 10(12):1246-54. PubMed ID: 18945637
    [Abstract] [Full Text] [Related]

  • 8. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure.
    Trikas A, Antoniades C, Latsios G, Vasiliadou K, Karamitros I, Tousoulis D, Tentolouris C, Stefanadis C.
    Eur J Heart Fail; 2006 Dec 23; 8(8):804-9. PubMed ID: 16713737
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?
    McLachlan CS, Mossop P.
    Eur J Heart Fail; 2006 Mar 23; 8(2):216-7; author reply 218. PubMed ID: 16488367
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ, Sun ZX, Su CY, Tan H, Zhong X, Hu B, Zhou Y, Shang DY.
    Cardiovasc Ther; 2013 Apr 23; 31(2):108-14. PubMed ID: 23490237
    [Abstract] [Full Text] [Related]

  • 13. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
    Nanas JN, Papazoglou PP, Terrovitis JV, Kanakakis J, Dalianis A, Tsolakis E, Tsagalou EP, Agrios N, Christodoulou K, Anastasiou-Nana MI.
    Am J Cardiol; 2004 Nov 15; 94(10):1329-32. PubMed ID: 15541261
    [Abstract] [Full Text] [Related]

  • 14. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G, Giannakoulas G, Tsarpalis K, Agha SA, Georgiopoulou V, Kalogeropoulos A, Karvounis H, Butler J.
    Int J Cardiol; 2008 Aug 01; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract] [Full Text] [Related]

  • 15. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
    Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, Pacher R.
    Eur J Heart Fail; 2007 Feb 01; 9(2):202-8. PubMed ID: 16859992
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L, Brito D, Matias JS, Madeira H.
    Rev Port Cardiol; 2007 Feb 01; 26(7-8):717-26. PubMed ID: 17939581
    [Abstract] [Full Text] [Related]

  • 17. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
    Celik T, Iyisoy A, Yuksel UC, Kardesoglu E.
    Int J Cardiol; 2008 Aug 01; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
    [Abstract] [Full Text] [Related]

  • 18. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H, Ozerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A, Akin M, Nazli C, Ergene O.
    Int J Clin Pract; 2008 Feb 01; 62(2):228-33. PubMed ID: 17949428
    [Abstract] [Full Text] [Related]

  • 19. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine.
    Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, Tandogan I.
    Cardiovasc Drugs Ther; 2007 Dec 01; 21(6):431-5. PubMed ID: 17952581
    [Abstract] [Full Text] [Related]

  • 20. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
    Mebazaa A, Erhardt L.
    Int J Clin Pract; 2003 Jun 01; 57(5):410-6. PubMed ID: 12846347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.